Penn Pharma targets June for completion of cold storage facility


Facility to double capacity of South Wales firm

Penn Pharma, a bioscience company headquartered in South Wales, is scheduled to complete its 15,000ft2 cold storage facility in Tredegar in June.

The facility will meet US Federal Drug Administration Good Manufacturing Practice (GMP) regulations.

Equipped with the latest technology, the cold storage facility will be powered by an essential services electrical supply with generator back up.

The cold storage unit will be large enough to accommodate secondary packaging and labelling processes.

The facility will be continually monitored and alarmed using 21CFR11-compliant wireless telemetry.

The construction of the cold store forms part of Penn’s £12m expansion, which has seen the company upgrade the site and improve transportation access.

Further plans for the expansion programme will be rolled out over the next five years inline with the firm’s growth.

Paul Thomas, chief scientific officer at Penn, said: ‘The significant cold storage facility will double our capacity and will strengthen our position as a leading contract development and manufacturing organisation (CDMO) in the UK and worldwide.’

‘We have heavily invested in the expansion of our Tredegar site and we look forward to our continued growth and expansion into the US.’

Penn Pharma, founded 30 years ago and based at Tredegar for the past 23 years, is a fully integrated pharmaceutical company, offering pharmaceutical development (formulation and analytical) services for highly specialised, clinical and commercial manufacturing along with complete clinical trial supply capabilities.